TSHA
HealthcareTaysha Gene Therapies, Inc.
$4.89
$-0.36 (-6.86%)
Jan 5, 2026
Price History (1Y)
Analysis
Taysha Gene Therapies, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $1.34B and approximately 73 employees. The company's financial health indicates significant net losses, with a Net Income (TTM) of -$99,929,000 and EBITDA of -$100,980,000. This is reflected in the Operating Margin of -1618.5% and Profit Margin of 0.0%. The Return on Equity (ROE) stands at -64.9%, while the Return on Assets (ROA) is -25.7%. The company's balance sheet reveals a significant cash position of $297.34M, accompanied by debt of $69.08M and a Debt to Equity ratio of 31.55. Taysha Gene Therapies' valuation metrics include a Price to Book ratio of 6.12 and a Price to Sales ratio of 212.28. The Forward P/E is -11.16, while the EV/EBITDA is -11.98.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Visit website →Key Statistics
- Market Cap
- $1.34B
- P/E Ratio
- N/A
- 52-Week High
- $6.02
- 52-Week Low
- $1.05
- Avg Volume
- 3.81M
- Beta
- 1.00
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 73